Navigation Links
OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Date:6/26/2012

r this year."

About OMS-I100

A total of up to 25 patients with Stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label, and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days one, five and eight with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

About Melanoma

The incidence of many common cancers is falling, but the incidence of melanoma continues to rise at a rate faster than that of any of the seven most common cancers. Between 1992 and 2004, melanoma incidence increased 45 percent, or 3.1 percent annually. An estimated 68,000 new cases of melanoma were diagnosed in the U.S. in 2010 — with nearly 8,700 resulting in death. Approximately 75 percent of skin cancer deaths are from melanoma. In 2004, the most recent figures available, the total direct medical cost associated with the treatment of skin cancer in the U.S. was $1.5 billion. Currently there are few treatment options for metastatic melanoma because of  the aggressive nature of the disease. Current treatment approaches are associated with high morbidity and only marginal improvements in overall survival.

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effec
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
5. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
6. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
9. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
10. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  Delays in the launch ... slow down the decision-making process, resulting in missed ... critical for biopharmaceutical companies to develop a tactical ... for quicker and more meaningful insights. ... LLC, nearly three-quarters of benchmarked study participants use ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 9, 2011 Novavax, Inc. (Nasdaq: NVAX ... Gregory Glenn, Chief Medical Officer of Novavax, will be ... A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial ... Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The ...
... 9, 2011 Americord Registry , a pioneer in ... proud to announce that it has obtained a provisional human ... Department of Health, becoming the first private umbilical cord blood ... collect umbilical cord blood in the state of New York. ...
Cached Medicine Technology:Americord Becomes Only Family Cord Blood Bank Headquartered in New York City to Hold State Cord Blood License 2
(Date:8/30/2015)... ... August 30, 2015 , ... ... been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould for ... proven professional, focused on your goals. Kathleen graduated from Florida State University ...
(Date:8/29/2015)... ... 30, 2015 , ... Electronic Informed Consent for Clinical Trials:, ... EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed consent is ... Clinical trial sites can now use audio, video and interactivity to educate participants ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... extend and improve the lives of patients, according to a newly published report. ... to read the full article. , The authors of the new paper ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 ... contains 15 seconds of unique footage that users can shrink and stretch in the ... and more. Users can customize color, brightness, scale, speed, range, and flare attributes with ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
Breaking Medicine News(10 mins):Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... But as pandemic seems to ebb, CDC notes a rise ... (HealthDay News) -- U.S. health officials said Monday that ... nationally, even as the number of American children dying from ... Monday by the U.S. Centers for Disease Control and Prevention ...
... , ... released today by Latino Decisions, the Robert Wood Johnson Foundation Center for ... shows a widespread consensus among the Latino/Hispanic electoral about the importance of ... the first time, health care tops the list of national issues identified ...
... , , ... Shock Doctor , is now required equipment in the Top Fuel, Funny ... Hot Rod Association (NHRA) Full Throttle Drag Racing Series, as well as ... NHRA Lucas Oil Drag Racing Series. Eject is the only ...
... ... , ... 30, 2009 -- The 18th annual Texas Autism Conference is set to be ... Bank Center., , , , ,The conference will bring 1,400 attendees and is expected to make ...
... SHORT HILLS, N.J., Nov. 30 Kemin Foods, L.C. ... Technologies, Ltd. ("OmniActive") have reached an amicable settlement of ... No. 5,382,714 ("the ,714 patent") titled "Process for Isolation, ... and Uses Thereof" and the reissues of that patent ...
... , , BRIDGEWATER, N.J., Nov. 30 ... meeting logistics, speaker programs and commercial compliance management software for ... second fastest growing company in the state by NJBIZ, New ... one of the top fifty businesses that have made significant ...
Cached Medicine News:Health News:U.S. Swine Flu Cases Chart Sharp Decline 2Health News:U.S. Swine Flu Cases Chart Sharp Decline 3Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 2Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 3Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 4Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 5Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 6Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 7Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 8Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 9Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:18th Annual Texas Autism Conference Returns To Corpus Christi, Makes Nearly $300,000 Economic Impact 2Health News:Advanced Health Media Honored at NJ Finest Award Ceremony 2
The Vivid e delivers everything you need in a compact echo system, like complete cardiovascular functionality, a comprehensive cardiac measurement and analysis package, and full shared service capabi...
BonePlast is a fast resorbing, osteoconductive bone void filler. By delivering a high dose of calcium to the operative site, BonePlast helps build new bone during the healing process. Packaged in a c...
... patented telescoping plate design integrates ... plate and vertebral column spacer. ... the need for supplemental fixation ... of bone graft to be ...
"Small" redefined for Holter recorders!...
Medicine Products: